Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily

Marco Paulli, Emilio Berti, Emanuela Boveri, Sandra Kindl, Emanuela Bonoldi, Claudio Gambini, Renato Rosso, Giovanni Borroni, Vincenzo Straccapansa, Umberto Magrini, John E. Decoteau, Peter H. Krammer, Peter Möller, Marshall E. Kadin

Research output: Contribution to journalArticlepeer-review

Abstract

The spectrum of CD30+ cutaneous lymphoproliferative disorders is characterized by the histology of a high-grade lymphoma but frequent clinical regression of skin lesions in lymphomatoid papulosis (LyP) and occasional regression in CD30+ large cell lymphomas (LCLs). A recent study shows that apoptosis may be a significant mechanism of regression of LyP (Arch Dermatol 133:828-833, 1997). Therefore, we studied expression of proteins that induce apoptosis, including CD27, CD40, CD95, and nerve growth factor receptor (NGF- R), as well as anti-apoptotic protein bcl-2 in skin lesions from 25 patients within the spectrum of CD30+ cutaneous lymphoma. Our results show consistent expression of CD95 (APO-1/Fas), but rare or absent expression of CD27, CD40, and NGF-R on tumor cells from both regressing LyP lesions and nonregressing CD30+ lymphomas. Bcl-2 was expressed at low levels in LyP and at high levels in pleomorphic CD30+ lymphomas. These results indicate that, in addition to CD30, CD95 expression is preferentially expressed at high levels in all cutaneous CD30+ lymphomas and suggest that CD95 may play a role in the regression of CD30+ skin lesions. Expression of bcl-2 appears to protect tumor cells from apoptosis in CD30+ lymphoproliferative disorders.

Original languageEnglish
Pages (from-to)1223-1230
Number of pages8
JournalHuman Pathology
Volume29
Issue number11
Publication statusPublished - 1998

Keywords

  • Bcl-2
  • CD30+ cutaneous lymphoproliferative disorders
  • Fas (CD95)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily'. Together they form a unique fingerprint.

Cite this